• Search History (Register)
  • MeSH Browser
  • [Clear]
    • Canada

Welcome to the international HTA database


Showing [3283 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) HbA1c testing frequency: a review of the clinical evidence and guidelines
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Narcotics, benzodiazepines, stimulants, and gabapentin: policies, initiatives, and practices across Canada, 2014
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Initiatives to optimize the utilization of laboratory tests
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Compression therapy in diabetic foot ulcer management: a review of clinical effectiveness, cost-effectiveness and guidelines
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Couples therapy for adults experiencing relationship distress: a review of the clinical evidence and guidelines
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Routine ordering of primary pathology examinations in Canada
2014     Health Quality Ontario (HQO) Effect of supportive interventions on informal caregivers of people at the end of life: a rapid review
2014     Health Quality Ontario (HQO) Team-based models for end-of-life care: an evidence-based analysis
2014     Health Quality Ontario (HQO) Patient care planning discussions for patients at the end of life: an evidence-based analysis
2014     Health Quality Ontario (HQO) End-of-life care interventions: an economic analysis
2014     Health Quality Ontario (HQO) Educational intervention in end-of-life care: an evidence-based analysis
2014     Health Quality Ontario (HQO) The determinants of place of death: an evidence-based analysis
2014     Health Quality Ontario (HQO) Cardiopulmonary resuscitation in patients with terminal illness: an evidence-based analysis
2014     Health Quality Ontario (HQO) Health care for people approaching the end of life: an evidentiary framework
2014     Health Quality Ontario (HQO) Arthroscopic debridement of the knee: an evidence update
2014     Health Quality Ontario (HQO) End-of-life health care in Ontario: OHTAC recommendation
2014     Health Quality Ontario (HQO) Arthroscopic debridement of the knee: OHTAC recommendation
2014     Institut national d'excellence en sante et en services sociaux (INESSS) [Use of long-term left ventricular assist devices for advanced heart failure in Quebec from 2010 to 2012]
2014     Institut national d'excellence en sante et en services sociaux (INESSS) [Portrait of the use of bisphosphonates and denosumab in patients aged 50 years or older with osteoporosis who are covered by the public prescription drug insurance program]
2014     Health Quality Ontario (HQO) Intra-articular analgesia after knee arthroscopy: a rapid review
2014     Health Quality Ontario (HQO) Bracing after knee arthroscopy: a rapid review
2014     Health Quality Ontario (HQO) Peripheral nerve blocks for post-operative pain relief after arthroscopic knee ligament reconstruction: a rapid review
2014     Health Quality Ontario (HQO) Preoperative shower or bath with antiseptics before knee arthroscopy: a rapid review
2014     Health Quality Ontario (HQO) Physiotherapy after knee arthroscopy: a rapid review
2014     Health Quality Ontario (HQO) Pre-emptive oral non-steroidal anti-inflammatory drugs or acetaminophen for knee arthroscopy: a rapid review
2014     Health Quality Ontario (HQO) Turning for ulcer reduction (TURN) study: an economic analysis
2014     Health Quality Ontario (HQO) Preventing pressure ulcers: a multisite randomized controlled trial in nursing homes
2014     Health Quality Ontario (HQO) Turning for the prevention and management of pressure ulcers: OHTAC Recommendation
2014     Institut national d'excellence en sante et en services sociaux (INESSS) [Stereotactic Body Radiation Therapy (SBRT)]
2014     Institut national d'excellence en sante et en services sociaux (INESSS) [Use of intravenous immunoglobulins - a review of management strategy experiences and the available evidence]
2014     Institut national d'excellence en sante et en services sociaux (INESSS) [Profile of individuals insured by the public prescription drug insurance plan who have received treatment for hepatitis C (HCV)]
2014     Technology Assessment Unit of the McGill University Health Centre (MUHC) Excimer laser atherectomy for uncrossable coronary lesions and improperly deployed coronary stents
2014     Technology Assessment Unit of the McGill University Health Centre (MUHC) Islet transplantation in patients with Type 1 Diabetes Mellitus
2014     Institute for Clinical Evaluative Sciences (ICES) 900,000 days in hospital: The annual impact of smoking, alcohol, diet and physical activity on hospital use in Ontario
2014     Institute for Clinical Evaluative Sciences (ICES) Ontario stroke evaluation report 2014: Ontario stroke report cards
2014     Institute for Clinical Evaluative Sciences (ICES) Health outcomes for better information and care (HOBIC): acute care and home care in Ontario 2013
2014     Institut national d'excellence en sante et en services sociaux (INESSS) [Change in the Proton Pump Inhibitors (PPI) terms for coverage: a follow-up]
2014     Institut national d'excellence en sante et en services sociaux (INESSS) [Addendum to the notice on the efficacy of rehabilitative interventions and pharmacological therapies for children aged 2 to 12 Years with autism spectrum disorder (ASD)]
2014     Institute of Health Economics (IHE) Effectiveness of screening for endemic antibiotic resistant organisms (AROs) in hospital settings
2014     Health Quality Ontario (HQO) Hemoglobin A1c testing in diabetes: a rapid review
2014     Health Quality Ontario (HQO) Preoperative resting echocardiography for noncardiac surgery: a rapid review
2014     Health Quality Ontario (HQO) Preoperative cardiac stress tests for noncardiac surgery: a rapid review
2014     Health Quality Ontario (HQO) Preoperative consultation: a rapid review
2014     Health Quality Ontario (HQO) Testing vitamin B12 levels in neuropathy, alopecia, dizziness, and fatigue: a rapid review
2014     Health Quality Ontario (HQO) Optical coherence tomography monitoring strategies for A-VEGF–treated age-related macular degeneration: OHTAC recommendation
2014     Health Quality Ontario (HQO) Hemoglobin A1c testing in diabetes: OHTAC recommendation
2014     Health Quality Ontario (HQO) Point-of-care hemoglobin A1c testing: OHTAC recommendation
2014     Health Quality Ontario (HQO) Optical coherence tomography monitoring strategies for A-VEGF–treated age-related macular degeneration: an evidence-based analysis
2014     Health Quality Ontario (HQO) Point-of-care hemoglobin A1c testing: a budget impact analysis
2014     Health Quality Ontario (HQO) Point-of-care hemoglobin A1c testing: an evidence-based analysis
2014     Institut national d'excellence en sante et en services sociaux (INESSS) [Lung cancer: investigation, treatment and follow-up algorithms]
2014     Institut national d'excellence en sante et en services sociaux (INESSS) [Use of Fertil ProMD products in the treatment of infertility]
2014     Institut national d'excellence en sante et en services sociaux (INESSS) [Effectiveness and safety of single-use protective sheaths for flexible nasopharyngolaryngoscopes]
2014     Institut national d'excellence en sante et en services sociaux (INESSS) [Digital Breast Tomosynthesis]
2014     Institut national d'excellence en sante et en services sociaux (INESSS) [Stereotactic ablative radiation therapy for the treatment of non-small cell lung cancer]
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Computed tomography-guided brachytherapy treatment in the operating room: clinical effectiveness, cost-effectiveness, and guidelines
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Hemodialysis chairs versus beds for patients at out-patient clinics: clinical evidence
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Maxillary artery ligation for the treatment of cluster or migraine headaches: clinical effectiveness and guidelines
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Goal setting tools for children: clinical effectiveness and guidelines
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Subsequent entry biologics — emerging trends in regulatory and health technology assessment frameworks
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Clinical review report. Ulipristal Acetate (Fibristal - Actavis Specialty Pharmaceuticals Co.) indication: uterine fibroids
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Pharmacoeconomic review report. Ulipristal Acetate (Fibristal - Actavis Specialty Pharmaceuticals Co.) indication: uterine fibroids
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Ulipristal Acetate (Fibristal - Actavis Specialty Pharmaceuticals Co.) indication: uterine fibroids
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Pharmacoeconomic review report. Saxagliptin (Onglyza - Bristol-Myers Squibb/AstraZeneca Canada Inc.) indication: type 2 diabetes mellitus
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Clinical review report. Saxagliptin (Onglyza - Bristol-Myers Squibb/AstraZeneca Canada Inc.) indication: type 2 diabetes mellitus
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Saxagliptin (Onglyza - Bristol-Myers Squibb/AstraZeneca Canada Inc.) indication: type 2 diabetes mellitus
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Dexmedetomidine for sedation of patients in the ICU or PICU: review of clinical effectiveness and safety
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Nicotine replacement therapy for smoking cessation or reduction: a review of the clinical evidence
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Montelukast for sleep apnea: a review of the clinical effectiveness, cost effectiveness, and guidelines
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Wireless device use and patient monitoring equipment in any healthcare delivery setting: a review of safety and guidelines
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) TECNIS® or Acrysof® soft intraocular lenses for patients undergoing cataract surgery: benefits and harms, clinical effectiveness, cost-effectiveness, and guidelines
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Intensivist response time to a closed intensive care unit: patient benefits and harms and guidelines
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Intranasal versus intravenous administration of anxiolytic or analgesic medications: comparative clinical effectiveness
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Smart infusion pump use in hospitalized patients: clinical safety and guidelines
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Compressible non-articulating disc prostheses in adult patients with degenerative disc disease: clinical effectiveness, safety, cost-effectiveness, and guidelines
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Oncotype DX in women and men with ER-positive HER2-negative early stage breast cancer Who are lymph node-positive: a review of clinical effectiveness and guidelines
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Buprenorphine/naloxone (Suboxone) film versus buprenorphine/naloxone tablets for the treatment of opioid addiction: comparative safety
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Positron emission tomography in neurology and cardiology: a review of guidelines and recommendations
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Paracentesis for the removal of peritoneal fluid: guidelines
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Flushing intravenous tubing post administration of medications: clinical evidence and guidelines
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Non-drug interventions for chronic non-cancer pain: guidelines and recommendations
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Drug interventions for chronic non-cancer pain: guidelines and recommendations
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Single-use medical devices reprocessed by third party/licenced reprocessors: patient benefits and harms, cost-effectiveness, and guidelines
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Icatibant for patients with type III hereditary angioedema: a review of clinical effectiveness and harms
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Next generation DNA sequencing: a review of the cost effectiveness and guidelines
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Magnetic resonance spectroscopic imaging for prostate disease detection: clinical and cost-effectiveness, and guidelines
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Trientine for treatment of Wilson's disease: clinical and cost-effectiveness, and safety
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Non-invasive prenatal testing: a review of the cost effectiveness and guidelines
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Interventions for non-elderly patients who are high users of ambulatory and emergency medical services: clinical and cost-effectiveness
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Nutritional supplementation for patients with cancer: a review of the clinical effectiveness and guidelines
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) iTClamp for controlling compressible gemorrhage in adults: clinical effectiveness, cost-effectiveness, and safety
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Viscosupplementation for the treatment of osteoarthritis of the knee: clinical effectiveness and guidelines
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Suboxone versus methadone for the detoxification of patients addicted to prescription opioids: a review of comparative clinical effectiveness, safety, and guidelines
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Lyophilized plasma for the treatment of adults with hemorrhagic shock: clinical and cost-effectiveness, safety, and guidelines
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Pharmacoeconomic review report. Lurasidone (Latuda - Sunovion Pharmaceuticals Inc.) indication: schizophrenia
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Clinical review report. Lurasidone (Latuda - Sunovion Pharmaceuticals Inc.) indication: schizophrenia
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Lurasidone (Latuda - Sunovion Pharmaceuticals Inc.) indication: schizophrenia
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Pharmacoeconomic review report. Somatropin (Genotropin - Pfizer Canada Inc.) indication: growth hormone deficiency in adults
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Clinical review report. Somatropin (Genotropin - Pfizer Canada Inc.) indication: growth hormone deficiency in adults
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Somatropin (Genotropin - Pfizer Canada Inc.) indication: long-term treatment of children who have growth failure due to an inadequate secretion of endogenous growth hormone